![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H32O2 |
Molar mass | 292.463 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
CGP-7930 was the first positive allosteric modulatorofGABAB receptors described in literature.[1][2][3][4] CGP7930 is also a GABAA receptor positive allosteric modulator and a blocker of Potassium channels.[5]
CGP7930 was developed in Novartis and has been used extensively for scientific research. It has anxiolytic effects in animal studies,[6][7] and has a synergistic effect with GABAB agonists such as baclofen and GHB,[8][9] as well as reducing self-administration of alcoholic drinks and cocaine.[10][11]